enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Roche joins race for obesity drugs with $2.7 billion Carmot deal

    www.aol.com/news/roche-enters-obesity-drug...

    Roche agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk ...

  3. Roche shares knocked by concern over side effects in obesity ...

    www.aol.com/news/roche-shares-drop-side-effects...

    Roche shares were trading 3.5% down by 0940 GMT, the second biggest faller on the pan-European STOXX 600 index, after the company presented details on the trial with once-daily pill CT-996 late on ...

  4. Roche - Wikipedia

    en.wikipedia.org/wiki/Roche

    F. Hoffmann-La Roche AG, commonly known as Roche (/ r ɒ ʃ /), is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company , Roche Holding AG , has shares listed on the SIX Swiss Exchange .

  5. List of largest pharmaceutical mergers and acquisitions

    en.wikipedia.org/wiki/List_of_largest...

    Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25.

  6. Ex-dividend date - Wikipedia

    en.wikipedia.org/wiki/Ex-dividend_date

    For instance, if the record date is Sunday, then the ex-dividend date is the preceding Thursday, not Friday — assuming no intervening holidays. To be a stockholder on the record date, an investor must purchase the stock before the ex-dividend date in order to allow for the 1-trading day settlement of the stock purchase. If the investor ...

  7. Roche open to big acquisitions 'if it makes scientific and ...

    www.aol.com/news/roche-open-big-acquisitions...

    Roche is open to making big acquisitions if they make "sense", Chief Executive Thomas Schinecker said, with the Swiss drugmaker unencumbered by its $20.7 billion deal last year to buy back its ...

  8. Genentech - Wikipedia

    en.wikipedia.org/wiki/Genentech

    In March 2009 Roche acquired Genentech by buying shares it didn't already control for approximately $46.8 billion. [ 16 ] [ 17 ] [ 18 ] In July 2014, Genentech/Roche acquired Seragon for its pipeline of small-molecule cancer drug candidates for $725 million cash upfront, with an additional $1 billion of payments dependent on successful ...

  9. The Roche Merger Will Do Wonders for Spark Stock - AOL

    www.aol.com/news/roche-merger-wonders-spark...

    Now that Spark Therapeutics (NASDAQ: ONCE) agreed on a definitive merger with Roche (OTCMKTS:RHHBY) for $114.50 a share, only one question remains for investors. Should investors keep holding ...